0.7012
price down icon2.35%   -0.0169
 
loading
Equillium Inc stock is traded at $0.7012, with a volume of 81,779. It is down -2.35% in the last 24 hours and down -37.39% over the past month. Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.
See More
Previous Close:
$0.7181
Open:
$0.69
24h Volume:
81,779
Relative Volume:
0.43
Market Cap:
$25.44M
Revenue:
$42.62M
Net Income/Loss:
$-8.32M
P/E Ratio:
-1.323
EPS:
-0.53
Net Cash Flow:
$-15.77M
1W Performance:
+2.48%
1M Performance:
-37.39%
6M Performance:
-53.56%
1Y Performance:
+40.58%
1-Day Range:
Value
$0.68
$0.7297
1-Week Range:
Value
$0.6637
$0.7683
52-Week Range:
Value
$0.4789
$3.25

Equillium Inc Stock (EQ) Company Profile

Name
Name
Equillium Inc
Name
Phone
(858) 412-5302
Name
Address
2223 AVENIDA DE LA PLAYA, LA JOLLA, CA
Name
Employee
45
Name
Twitter
Name
Next Earnings Date
2024-08-08
Name
Latest SEC Filings
Name
EQ's Discussions on Twitter

Compare EQ with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
EQ 0.7012 25.44M 42.62M -8.32M -15.77M -0.53
VRTX 448.26 115.74B 10.63B -479.80M -1.35B 13.33
REGN 744.88 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 592.97 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 248.80 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 103.82 24.49B 3.30B -501.07M 1.03B 11.54

Equillium Inc Stock (EQ) Upgrades & Downgrades

Date Action Analyst Rating Change
Oct-29-21 Resumed Stifel Buy
Sep-15-21 Initiated Cantor Fitzgerald Overweight
Jul-14-20 Reiterated H.C. Wainwright Buy
Jul-10-20 Resumed Stifel Buy
Feb-22-19 Initiated SVB Leerink Outperform

Equillium Inc Stock (EQ) Latest News

pulisher
Nov 16, 2024

Why Investors Shouldn't Be Surprised By Equillium, Inc.'s (NASDAQ:EQ) 35% Share Price Plunge - Simply Wall St

Nov 16, 2024
pulisher
Nov 15, 2024

Equillium CFO Jason Keyes sells $7,000 in stock By Investing.com - Investing.com UK

Nov 15, 2024
pulisher
Nov 15, 2024

Equillium CFO Jason Keyes sells $7,000 in stock - Investing.com

Nov 15, 2024
pulisher
Nov 13, 2024

Equillium’s Q3 Financials and Clinical Progress in Focus - TipRanks

Nov 13, 2024
pulisher
Nov 13, 2024

Equillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical Updates - The Bakersfield Californian

Nov 13, 2024
pulisher
Nov 13, 2024

Equillium Q3 Revenue Jumps 37% to $12.2M, Slashes Net Loss as Pipeline Advances | EQ Stock News - StockTitan

Nov 13, 2024
pulisher
Nov 13, 2024

Equillium to Present at the Stifel Healthcare Conference - The Bakersfield Californian

Nov 13, 2024
pulisher
Nov 13, 2024

Equillium to Present Clinical Pipeline Updates at Stifel Healthcare Conference | EQ Stock News - StockTitan

Nov 13, 2024
pulisher
Nov 13, 2024

Equillium Announces Poster Presentation at the Society for Immunotherapy of Cancer - BioSpace

Nov 13, 2024
pulisher
Nov 12, 2024

Equillium Reveals Breakthrough Immune Response Data at Major Cancer Conference | EQ Stock News - StockTitan

Nov 12, 2024
pulisher
Nov 09, 2024

Equillium, Inc. (EQ) to Report Q3 Results: Wall Street Expects Earnings Growth - MSN

Nov 09, 2024
pulisher
Nov 05, 2024

Equillium keeps equilibrium in GVHD after Ono no-go - BioWorld Online

Nov 05, 2024
pulisher
Nov 02, 2024

Equillium says Ono not acquiring itolizumab, stock craters 36% - MSN

Nov 02, 2024
pulisher
Nov 01, 2024

Ono says no to Equillium’s itolizumab - The Pharma Letter

Nov 01, 2024
pulisher
Nov 01, 2024

Jones Trading Downgrades Equillium (EQ) - MSN

Nov 01, 2024
pulisher
Nov 01, 2024

Equillium retains rights to itolizumab after Ono's option expires - Investing.com India

Nov 01, 2024
pulisher
Oct 31, 2024

Equillium shares downgraded to hold from buy By Investing.com - Investing.com Canada

Oct 31, 2024
pulisher
Oct 31, 2024

Equillium shares downgraded to hold from buy - Investing.com India

Oct 31, 2024
pulisher
Oct 31, 2024

Equillium says Ono not acquiring itolizumab, stock craters 36% (NASDAQ:EQ) - Seeking Alpha

Oct 31, 2024
pulisher
Oct 31, 2024

Equillium Maintains Rights to Itolizumab Following Ono Partnership - Business Wire

Oct 31, 2024
pulisher
Oct 31, 2024

Equillium COO Christine Zedelmayer sells $18,750 in stock - Investing.com

Oct 31, 2024
pulisher
Oct 31, 2024

Equillium COO Christine Zedelmayer sells $18,750 in stock By Investing.com - Investing.com Australia

Oct 31, 2024
pulisher
Oct 31, 2024

LogoEquillium Maintains Rights to Itolizumab Following Ono Partnership - Business Wire

Oct 31, 2024
pulisher
Oct 31, 2024

Insider Sale: Sr. Vice President and COO Christine Zedelmayer Se - GuruFocus.com

Oct 31, 2024
pulisher
Oct 22, 2024

Alto Ingredients And 2 Other US Penny Stocks To Watch Closely - Simply Wall St

Oct 22, 2024
pulisher
Oct 19, 2024

Moleculin Biotech (NASDAQ:MBRX) versus Equillium (NASDAQ:EQ) Financial Comparison - Defense World

Oct 19, 2024
pulisher
Oct 13, 2024

Renaissance Technologies LLC Acquires 91,200 Shares of Equillium, Inc. (NASDAQ:EQ) - Defense World

Oct 13, 2024
pulisher
Oct 07, 2024

Equillium Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer - StockTitan

Oct 07, 2024
pulisher
Sep 27, 2024

Equillium CFO Jason Keyes sells $8,100 in company stock By Investing.com - Investing.com South Africa

Sep 27, 2024
pulisher
Sep 27, 2024

Equillium CFO Jason Keyes sells $8,100 in company stock - Investing.com India

Sep 27, 2024
pulisher
Sep 26, 2024

Lacklustre Performance Is Driving Equillium, Inc.'s (NASDAQ:EQ) 28% Price Drop - Simply Wall St

Sep 26, 2024
pulisher
Sep 22, 2024

Graft versus Host Disease Market to Increase at a CAGR of 9.9% During the Study Period (2020–2034) | DelveInsight - GlobeNewswire Inc.

Sep 22, 2024
pulisher
Sep 18, 2024

Equillium executive sells $32,985 in stock - Investing.com India

Sep 18, 2024
pulisher
Sep 17, 2024

Equillium executive sells $32,985 in stock By Investing.com - Investing.com Australia

Sep 17, 2024
pulisher
Sep 17, 2024

Equillium collaborates with Vivtex for oral formulation of autoimmune therapy - Yahoo Finance

Sep 17, 2024
pulisher
Sep 16, 2024

Vivtex Enters New Research Agreement with Equillium to Develop GI-targeted Formulations for its First-in-Class Oral, Bi-Specific Peptide Therapy - ForexTV.com

Sep 16, 2024
pulisher
Sep 10, 2024

Equillium to Present at the Stifel Virtual Inflammation & Immunology Summit - StockTitan

Sep 10, 2024
pulisher
Sep 04, 2024

Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Sep 04, 2024
pulisher
Sep 02, 2024

Wall Street analysts’ outlook for Equillium Inc (EQ) - SETE News

Sep 02, 2024
pulisher
Sep 02, 2024

Equillium Inc’s Market Journey: Closing Weak at 1.07, Down -0.93 - The Dwinnex

Sep 02, 2024
pulisher
Sep 02, 2024

How should investors view Equillium Inc (EQ)? - US Post News

Sep 02, 2024
pulisher
Aug 30, 2024

Equillium Inc Inc. (EQ) Price Performance: A Fundamental Analysis Perspective - The InvestChronicle

Aug 30, 2024
pulisher
Aug 28, 2024

Equillium to Present at the Wells Fargo Healthcare Conference and the H.C. Wainwright 26th Annual Global Investor Conference - StockTitan

Aug 28, 2024
pulisher
Aug 28, 2024

Equillium to Present at the Wells Fargo Healthcare Conference and the H.C. Wainwright 26 - Business Wire

Aug 28, 2024
pulisher
Aug 21, 2024

Q3 2024 Earnings Forecast for Equillium, Inc. (NASDAQ:EQ) Issued By HC Wainwright - Defense World

Aug 21, 2024
pulisher
Aug 20, 2024

Equillium, Inc. (NASDAQ:EQ) Forecasted to Post FY2024 Earnings of $0.62 Per Share - Defense World

Aug 20, 2024
pulisher
Aug 19, 2024

Equillium’s (EQ) Buy Rating Reiterated at HC Wainwright - Defense World

Aug 19, 2024
pulisher
Aug 14, 2024

Equillium Presents Positive Interim Clinical Data of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease at the 2021 Transplantation and Cellular Therapy Meetings Digital Experience - Marketscreener.com

Aug 14, 2024
pulisher
Aug 11, 2024

Equillium Second Quarter 2024 Earnings: Beats Expectations - Simply Wall St

Aug 11, 2024
pulisher
Aug 10, 2024

Equillium (NASDAQ:EQ) Issues Quarterly Earnings Results, Beats Estimates By $0.16 EPS - Defense World

Aug 10, 2024

Equillium Inc Stock (EQ) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$70.68
price down icon 0.42%
$18.62
price up icon 0.16%
$36.06
price down icon 1.68%
$364.60
price up icon 0.01%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Cap:     |  Volume (24h):